← Back to All Calculators
eGFR — CKD-EPI 2021
Race-free Chronic Kidney Disease Epidemiology Collaboration equation
Patient Parameters
Enter a valid creatinine (0.1–30)
Enter age 18–120
—
mL/min/1.73m²
CKD Staging & Drug Dosing Implications
| Stage | eGFR (mL/min/1.73m²) | Description | Drug Dosing Impact |
|---|---|---|---|
| G1 | ≥ 90 | Normal or high | Standard dosing |
| G2 | 60–89 | Mildly decreased | Monitor; minimal dose adjustment |
| G3a | 45–59 | Mild-moderately decreased | Adjust renally-cleared drugs |
| G3b | 30–44 | Moderate-severely decreased | Reduce doses; avoid nephrotoxins |
| G4 | 15–29 | Severely decreased | Significant reductions; prepare for RRT |
| G5 | < 15 | Kidney failure | Dialysis doses; many drugs contraindicated |
CKD-EPI 2021 Formula (race-free):
κ = 0.7 (F) or 0.9 (M) | α = −0.241 (F) or −0.302 (M)
eGFR = 142 × min(Scr/κ, 1)α × max(Scr/κ, 1)−1.200 × 0.9938Age × 1.012 [if female]
κ = 0.7 (F) or 0.9 (M) | α = −0.241 (F) or −0.302 (M)
eGFR = 142 × min(Scr/κ, 1)α × max(Scr/κ, 1)−1.200 × 0.9938Age × 1.012 [if female]
Clinical Notes: CKD-EPI 2021 is preferred over MDRD and the 2009 race-based equation. It is more accurate at higher GFR values. CKD staging requires confirmation over ≥3 months. eGFR should be used alongside albuminuria (ACR) for complete CKD classification.
